the Aval
Technology adoption decision record & value contract
Fairhaven General Hospital — Demo
Brantwood, ON
AC-2025-047
Antimicrobial foam dressing substitution
Silver foam dressing line substitution — DermaCare · Wound Care · requested by Jenna Kowalski, NP, Nov 25, 2025
Approved
Dec 16, 2025
Equivalent clinical performance in sample evaluation; 19% category saving. Delegated fast-track authority.
Committee record: 3 for · 0 against · 0 abstentions
Problem addressed
Incumbent silver foam line repriced +18% at renewal; equivalent products available at lower cost with better conformability feedback.
Standard replaced or augmented
Incumbent silver foam dressing line.
Evidence basis
- Sample evaluation on file.
Value profile at decision
| Clinical impact | 2/5 · w30% |
| Safety | 2/5 · w25% |
| Financial materiality | 3/5 · w20% |
| Workflow disruption | 1/5 · w15% |
| Organizational risk | 1/5 · w10% |
Net annual impact: +$14K/yr (assumptions on case file)
Value contract
Frozen Dec 16, 2025 · reviews at 90 days · immutable
| We approved this technology expecting | Baseline | Expected |
|---|---|---|
| Cost per treated wound | 18.4 $ | ≤ 15.1 $ |
| Dressing-related irritation reports | 6 /mo | ≤ 4 /mo |
| Clinician adoption | 0 % | ≥ 85 % |
Sarah Okafor
Director, Value Analysis
Alan Chen
VP, Supply Chain & Facilities
This Aval is the permanent institutional record of this adoption decision: what was decided, on what evidence, by whom, and against which expected outcomes it will be measured. Audit trail: 5 events on file. Generated by Aval — Aug 13, 2026. Contains no patient-level information.